Avutometinib Plus Defactinib Generates Responses in ...
The combination of avutometinib and defactinib showed a 28% ORR in recurrent low-grade serous ovarian cancer patients, with a 93% DCR. KRAS-mutated and wild-type patients had similar ORRs. The FDA chose the combination over monotherapy for further analysis. Verastem Oncology plans to use RAMP-201 and FRAME trial data for potential accelerated approval. The treatment was well-tolerated, with common AEs being mild to moderate.
Related Clinical Trials
Reference News
The combination of avutometinib and defactinib showed a 28% ORR in recurrent low-grade serous ovarian cancer patients, with a 93% DCR. KRAS-mutated and wild-type patients had similar ORRs. The FDA chose the combination over monotherapy for further analysis. Verastem Oncology plans to use RAMP-201 and FRAME trial data for potential accelerated approval. The treatment was well-tolerated, with common AEs being mild to moderate.